Clinical Trial Update: Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005) [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and immunogenicity of the tetravalent dengue vaccine V180 in adults previously vaccinated with TV003 or TV005; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• TV003
• TV005
• V180

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED